Back to search

Peptide record

TPDB13412

Brevinin-1GHd Brevinin-1HL Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13412
Brevinin-1GHd Brevinin-1HL
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifungipept CAFPdb dbAMP PD_Hemolysis ToxinPred 3.0
standard
No
A 24-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, DRAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
FLGALFKVASKLVPAAICSISKKC
Physicochemical Analysis
C116H196N28O28S2
RNDEQHMTWY
AK
2495.12
10.17
4
0
13
+4
-0.77
1.108
122.08
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
125
5.01
5
Residue Composition
number
4
A
0
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
2
I
3
L
4
K
0
M
2
F
1
P
3
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 4 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 2 L: 3 K: 4 M: 0 F: 2 P: 1 S: 3 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
24
C116H196N28O28S2
2495.12
10.17
+4
-0.77
1.108
Free
L
Linear
Free
Antimicrobial
Hylarana guentheri Hylarana latouchii
Evidence Records 20 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2-4 µM

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
DRAMP antibacterial activity supported by MIC records against bacterial target organisms. dbAMP classified as Antibacterial under the Anti-bacterial function class.
Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and
Evidence 2 Activity

Activity

MIC
Antibacterial
8 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammat
Evidence 3 Activity

Activity

MIC
Antibacterial
32 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammatory effects by suppressing
Evidence 4 Activity

Activity

MIC
Antibacterial
4 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

ve against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammatory effects by suppressing the release of TNF-alpha
Evidence 5 Activity

Activity

IC50
IC50 = 2.987 µM
Anticancer
2.987 µM

Target

Lung Cancer
NCI-H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2020

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 6 Activity

Activity

IC50
IC50 = 7.985 µM
Anticancer
7.985 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2020
Evidence 7 Activity

Activity

IC50
IC50 = 1.197 µM
Anticancer
1.197 µM

Target

Skin Cancer
MDA-MB-435S
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2020
Evidence 8 Activity

Activity

IC50
IC50 = 9.854 µM
Anticancer
9.854 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2020
Evidence 9 Activity

Activity

IC50
IC50 = 8.52 ± 1.02 µM
Anticancer
8.52

Target

Lung Cancer
NCI-H23
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2020
Evidence 10 Activity

Activity

MIC
Antifungal
2-4 µM

Target

Staphylococcus aureus or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
DRAMP antifungal activity supported by activity records against fungal target organisms. dbAMP classified under the Anti-fungal function class.
Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and
Evidence 11 Activity

Activity

MIC
Antifungal
8 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammat
Evidence 12 Activity

Activity

MIC
Antifungal
32 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammatory effects by suppressing
Evidence 13 Activity

Activity

MIC
Antifungal
4 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ve against S. aureus or MRSA (MIC 2-4 uM), E. coli (MIC 8 uM), P. aeruginosa (MIC 32 uM), C. albicans (MIC 4 uM). It binds LPS and shows anti-inflammatory effects by suppressing the release of TNF-alpha
Evidence 14 Activity

Activity

% Hemolysis
Hemolysis
13 36 64 83 108 %
[Ref.32347293] Brevinin-1GHd displayed 13% hemolysis on horse red blood cells at its highest MIC/MBC value of the tested bacteria P. aeruginosa (32 µM). However, when the concentration increased above 64 µM, the hemolytic activity of Brevinin-1GHd also gradually increased. At the concentration of 64, 128, 256 and 512 µM, it displayed about 36%, 64%, 83% and 108% hemolysis.

Target

horse red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Biosci Rep. 2020 May 29 40(5):BSR20200019. doi: 10.1042/BSR20200019.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 15 Activity

Activity

50% Cell death
Toxicity
15.62 µM
Cytotoxic
50% Cell death | 15.62 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
Brevinin-1GHd: a novel Hylarana guentheri skin secretion-derived Brevinin-1 type peptide with antimicrobial and anticancer therapeutic potential. | Biosci Rep | 2020
Evidence 16 Activity

Activity

50% Cell death
Toxicity
29.69 µM
Cytotoxic
50% Cell death | 29.69 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Brevinin-1GHd: a novel Hylarana guentheri skin secretion-derived Brevinin-1 type peptide with antimicrobial and anticancer therapeutic potential. | Biosci Rep | 2020
Evidence 17 Activity

Activity

13% Hemolysis
Toxicity
32 µM
Hemolytic Cytotoxic
13% Hemolysis | 32 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Brevinin-1GHd: a novel Hylarana guentheri skin secretion-derived Brevinin-1 type peptide with antimicrobial and anticancer therapeutic potential. | Biosci Rep | 2020
Evidence 18 Activity

Activity

50% Hemolysis
Toxicity
96 µM
Hemolytic Cytotoxic
50% Hemolysis | 96 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Brevinin-1GHd: a novel Hylarana guentheri skin secretion-derived Brevinin-1 type peptide with antimicrobial and anticancer therapeutic potential. | Biosci Rep | 2020
Evidence 19 Activity

Activity

% Hemolysis
Toxicity
13 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.32347293] Brevinin-1GHd displayed 13% hemolysis on horse red blood cells at its highest MIC/MBC value of the tested bacteria P. aeruginosa (32 µM). However, when the concentration increased above 64 µM, the hemolytic activity of Brevinin-1GHd also gradually increased. At the concentration of 64, 128, 256 and 512 µM, it displayed about 36%, 64%, 83% and 108% hemolysis. | Cytotoxicity: [Ref.32347293]Brevinin-1GHd showed significant cytotoxicity toward human HMEC-1 and HaCaT cells at concentrations of 0.00001 and 0.0001 M, respectively. Brevinin-1GHd induced one cell viability of 56% on HMEC-1 and the other cell viability of 75% on HaCat.

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2020 May 29 40(5):BSR20200019. doi: 10.1042/BSR20200019.
Evidence 20 Hemolysis

Activity

13 36 64 83 108 %
% Hemolysis
[Ref.32347293] Brevinin-1GHd displayed 13% hemolysis on horse red blood cells at its highest MIC/MBC value of the tested bacteria P. aeruginosa (32 µM). However, when the concentration increased above 64 µM, the hemolytic activity of Brevinin-1GHd also gradually increased. At the concentration of 64, 128, 256 and 512 µM, it displayed about 36%, 64%, 83% and 108% hemolysis.
Hemolysis

Target

horse red blood cells

Source & Reference

PD_Hemolysis
Biosci Rep. 2020 May 29 40(5):BSR20200019. doi: 10.1042/BSR20200019.
DRAMP4
PD_Hemolysis